Byron L Lam1, William J Feuer2, Janet L Davis2, Vittorio Porciatti2, Hong Yu2, Robert B Levy2, Elizabeth Vanner2, John Guy2. 1. From the Bascom Palmer Eye Institute (B.L.L., W.J.F., J.L.D., V.P., H.Y., E.V., J.G.) and Department of Microbiology and Immunology (R.B.L.), University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: blam@med.miami.edu. 2. From the Bascom Palmer Eye Institute (B.L.L., W.J.F., J.L.D., V.P., H.Y., E.V., J.G.) and Department of Microbiology and Immunology (R.B.L.), University of Miami Miller School of Medicine, Miami, Florida, USA.
Abstract
PURPOSE: To assess safety of gene therapy in G11778A Leber hereditary optic neuropathy (LHON). DESIGN: Phase 1 clinical trial. METHODS: Setting: single institution. PARTICIPANTS: Patients with G11778A LHON and chronic bilateral visual loss >12 months (group 1, n = 11), acute bilateral visual loss <12 months (group 2, n = 9), or unilateral visual loss (group 3, n = 8). INTERVENTION: unilateral intravitreal AAV2(Y444,500,730F)-P1ND4v2 injection with low, medium, high, and higher doses to worse eye for groups 1 and 2 and better eye for group 3. OUTCOME MEASURES: Best-corrected visual acuity (BCVA), adverse events, and vector antibody responses. Mean follow-up was 24 months (range, 12-36 months); BCVAs were compared with a published prospective natural history cohort with designated surrogate study and fellow eyes. RESULTS: Incident uveitis (8 of 28, 29%), the only vector-related adverse event, resulted in no attributable vision sequelae and was related to vector dose: 5 of 7 (71%) higher-dose eyes vs 3 of 21 (14%) low-, medium-, or high-dose eyes (P < .001). Incident uveitis requiring treatment was associated with increased serum AAV2 neutralizing antibody titers (p=0.007) but not serum AAV2 polymerase chain reaction. Improvements of ≥15-letter BCVA occurred in some treated and fellow eyes of groups 1 and 2 and some surrogate study and fellow eyes of natural history subjects. All study eyes (BCVA ≥20/40) in group 3 lost ≥15 letters within the first year despite treatment. CONCLUSIONS: G11778A LHON gene therapy has a favorable safety profile. Our results suggest that if there is an efficacy effect, it is likely small and not dose related. Demonstration of efficacy requires randomization of patients to a group not receiving vector in either eye.
PURPOSE: To assess safety of gene therapy in G11778A Leber hereditary optic neuropathy (LHON). DESIGN: Phase 1 clinical trial. METHODS: Setting: single institution. PARTICIPANTS: Patients with G11778A LHON and chronic bilateral visual loss >12 months (group 1, n = 11), acute bilateral visual loss <12 months (group 2, n = 9), or unilateral visual loss (group 3, n = 8). INTERVENTION: unilateral intravitreal AAV2(Y444,500,730F)-P1ND4v2 injection with low, medium, high, and higher doses to worse eye for groups 1 and 2 and better eye for group 3. OUTCOME MEASURES: Best-corrected visual acuity (BCVA), adverse events, and vector antibody responses. Mean follow-up was 24 months (range, 12-36 months); BCVAs were compared with a published prospective natural history cohort with designated surrogate study and fellow eyes. RESULTS: Incident uveitis (8 of 28, 29%), the only vector-related adverse event, resulted in no attributable vision sequelae and was related to vector dose: 5 of 7 (71%) higher-dose eyes vs 3 of 21 (14%) low-, medium-, or high-dose eyes (P < .001). Incident uveitis requiring treatment was associated with increased serum AAV2 neutralizing antibody titers (p=0.007) but not serum AAV2 polymerase chain reaction. Improvements of ≥15-letter BCVA occurred in some treated and fellow eyes of groups 1 and 2 and some surrogate study and fellow eyes of natural history subjects. All study eyes (BCVA ≥20/40) in group 3 lost ≥15 letters within the first year despite treatment. CONCLUSIONS: G11778A LHON gene therapy has a favorable safety profile. Our results suggest that if there is an efficacy effect, it is likely small and not dose related. Demonstration of efficacy requires randomization of patients to a group not receiving vector in either eye.
Authors: Nancy J Newman; Patrick Yu-Wai-Man; Valerio Carelli; Mark L Moster; Valerie Biousse; Catherine Vignal-Clermont; Robert C Sergott; Thomas Klopstock; Alfredo A Sadun; Piero Barboni; Adam A DeBusk; Jean François Girmens; Günther Rudolph; Rustum Karanjia; Magali Taiel; Laure Blouin; Gerard Smits; Barrett Katz; José-Alain Sahel Journal: Ophthalmology Date: 2021-01-12 Impact factor: 12.079
Authors: Giovanni Manfredi; Jin Fu; Joseline Ojaimi; James E Sadlock; Jennifer Q Kwong; John Guy; Eric A Schon Journal: Nat Genet Date: 2002-02-25 Impact factor: 38.330
Authors: Byron L Lam; William J Feuer; Joyce C Schiffman; Vittorio Porciatti; Ruth Vandenbroucke; Potyra R Rosa; Giovanni Gregori; John Guy Journal: JAMA Ophthalmol Date: 2014-04-01 Impact factor: 7.389
Authors: William J Feuer; Joyce C Schiffman; Janet L Davis; Vittorio Porciatti; Phillip Gonzalez; Rajeshwari D Koilkonda; Huijun Yuan; Anil Lalwani; Byron L Lam; John Guy Journal: Ophthalmology Date: 2015-11-19 Impact factor: 12.079
Authors: Nancy J Newman; Patrick Yu-Wai-Man; Valerio Carelli; Valerie Biousse; Mark L Moster; Catherine Vignal-Clermont; Robert C Sergott; Thomas Klopstock; Alfredo A Sadun; Jean-François Girmens; Chiara La Morgia; Adam A DeBusk; Neringa Jurkute; Claudia Priglinger; Rustum Karanjia; Constant Josse; Julie Salzmann; François Montestruc; Michel Roux; Magali Taiel; José-Alain Sahel Journal: Front Neurol Date: 2021-05-24 Impact factor: 4.003